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Abstract 
Introduction: Liver dysfunction is implicated with the use of Antituberculosis 
(AT) leading to low compliance of TB patients to AT regimen. One of biomarker 
that is important to measure liver dysfunction is total bilirubin serum. Paliasa 
leaves have been emiprically used to improve liver function in South Sulawesi. 
This study aimed to determine the effect of ethanolic extract of Paliasa leaves on 
total bilirubin serum in rats.  
Method: Twenty rats were devided into five groups: Group I served as the 
healthy control was only given NaCMC suspension, group II was treated with 
178 mg/200g of AT suspension, while group III, group IV and group V  were 
given Paliasa extract 125 mg/kgBB, 250mg/kgBB and 500 mg/kgBB, 
respectively, 4 hours prior to AT administration. Treatments were performed 
once a day for 28 days. Blood sampling was carried out 24 hours following the 
last treatment. The total bilirubin levels were measured using Humalyzer 3500.  
Result: The results showed that the administrations of AT suspension for 28 days 
significantly increased rat total bilirubin levels. Paliasa leaf extract in all given 
dose was able to reduce the total bilirubin levels of rats compared to the group 
treated with AT only . However, statistical significance was only reached by the 
groups that were treated with Paliasa extract 500 mg/kg.  
Conclusion: Therefore, it is concluded that Paliasa extract at a dose of 500 mg/kg 
has protective effect against AT-induced elevation of total bilirubin serum in rats.
INTRODUCTION 
Liver is the main metabolic organ of the body, 
which has complex functions in regulating the 
metabolism of nutrition, drugs or toxic 
compounds. As most drugs are metabolized in the 
liver, it becomes vulnerable to drug-induced liver 
injury, especially when the drugs produce toxic 
metabolites.1 The presence of liver injury or  
 
damage is mainly detected by the elevation of 
liver enzymes in the serum, including alanine 
transaminase (ALT) and aspartate transaminase 
(AST). In addition, serious malfunction of the 
liver can manifest in hyperbilirubemia due to the 
dysfunctional uptake, conjugation and excretion 
of bilirubin.2 If the concentration of bilirubin 
serum significantly elevates, it diffuses to the 
surrounding tissues leading to yellowish 
appearance of the skin and mucous membranes, 
commonly called as jaundice.3  
 
The first line of antituberculosis regimen 
composes of Isoniazid (INH), Rifampicin (RIF), 
Pyrazinamid (PZA) and Ethambutol (EMB). 
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Three of the four drugs (INH, RIF and PZA) are 
known to possess capability to harm liver 
function4. As a result, high incidence of 
hepatotoxicity is found among tuberculosis 
patients treated with AT drugs around the world 5-
7, affecting children and adult patients.8  
 
Paliasa (Kleinhovia hospita L.) is a native plant 
from South Sulawesi that has been used 
traditionally to treat jaundice and hepatitis.9 Four 
cycloartane triterpenoid alkaloids have been 
isolated from Kleinhovia Hospita, i.e 
Kleinhospitines A, B, C and D, and these 
compounds have been shown to be protective 
against H2O2 radical induced damage in 
hepatocyte cell culture.10 In the previous study, 
Paliasa leaf extract with the dose of 250 mg/kg 
and 500 mg/kgBB were found to have the ability 
to reduce liver cell damage caused by carbon 
tetrachloride (CCI4).11 More currently data on 
paliasa leaf extract also showed a superior 
protection against doxorubicine-induced 
hepatotoxicity with a dose of 250 and 500 
mg/kg.12 However, there is still limited data 
exploring the capacity of Paliasa leaf extract on 
preventing hyperbilirubinemia, especially those 
induced by AT drugs. Therefore, the aim of this 
study is to determine the effect of Paliasa leaf 
extract on serum total bilirubin in rats treated with 
toxic dose of AT drugs.  
 
METHODS 
 
Animal preparation 
Twenty male rats weighed 150-200 g were used in 
the study. The animals were fed with standard 
pellets and drink ad libitum. The animal care 
protocols were carried out based on institution 
animal standard of care. Rats were acclimatized 
for 14 days prior to treatment. 
 
Drug preparation 
Antituberculosis was purchased in fixed dose 
combination (Rifastar®) in a local pharmacy. The 
tablets were pulverized and suspended in NaCMC 
1% to facilitate oral gauge in rats. The AT 
suspension was made with 8.9 g of AT in 100 ml 
suspension (8.9%). The preparation of suspension 
was done on daily basis. 
 
Extract Preparation 
Paliasa (Kleinhovia hospita L.) leaves were 
obtained in Makassar. The samples were washed 
using tap water and dried in an oven (40oC) before 
macerated in 70% ethanol (sample: ethanol = 
1:10) for 24 hours followed by re-maceration for 
another 24 hours. The extract obtained was 
evaporated using a rotary evaporator (Heidolp®) 
to form a thick extract. The extract was kept in a 
desiccator at room temperature to prevent it from 
excessive humidity. Immediately prior to 
treatment, the extract was prepared in 1% NaCMC 
suspension. 
 
Experimental protocols 
Animals (n=20) were assigned in 1 of 5 groups. 
Group I served as healthy control group was only 
given 1% NaCMC suspension.  Group II was 
treated with 178 mg/kg of AT drug suspension. 
Group 3 was treated with Paliasa leaf extract 125 
mg/kg prior to AT drug administration.  Group 4 
was treated with Paliasa leaf extract 250 mg/kg 
prior to AT drug administration. Group 5 was 
treated with Paliasa leaf extract 500 mg/kg prior 
to AT drug administration. All treatments were 
carried out for 28 days. Blood samples were 
withdrawn 24 hours following the last treatment. 
In addition, blood samples were randomly taken 
from nine healthy rats prior to treatment to 
measure baseline bilirubin level. The total 
bilirubin serum was measured using Humalyzer 
3500 with Total Bilirubin Reagent® and T-Nitrite 
Reagent (Human®). 
  
Statistical analysis 
Data is presented in mean ± SD. Statistical 
analysis was performed using SPSS 24. The 
distribution of data was determined using 
Kolmogorov Smirnov analysis. Data then 
analyzed with One-way ANOVA. The significant 
difference between treatment groups was 
analyzed using post hoc Bonferonni test. 
Statistical significance is achieved if p<0.05. 
 
RESULTS 
 
Baseline serum total bilirubin  
In this study, the level of serum total bilirubin was 
measured using Humalyzer 3500. For healthy 
wistar rats, it is found that serum total bilirubin 
ranged from 0.090-0.205 mg/dl with the average 
of 0.613 ± 0.045 (Table 1). 
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Table 1. Serum total bilirubin in healthy rats 
measured using Humalyzer 3500 
 
Rat 
Total 
bilirubin 
serum 
(mg/dl) 
Range 
(mg/dl) 
Mean 
(mg/dl) 
Standard 
Deviation 
1 0.237 
0.090-
0.205 0.163 0.045 
2 0.090 
3 0.198 
4 0.130 
5 0.157 
6 0.205 
7 0.170 
8 0.159 
9 0.125 
 
Serum total bilirubin after treatments 
Following 28 days of treatments, it is shown that 
rats that were only given NaCMC (healthy 
controls) had total bilirubin level within the 
baseline range (Figure 1). Meanwhile, rats that 
were treated with AT 178 mg/kg daily had 
significantly increased total bilirubin level. The 
mean level of total bilirubin in AT group was 
more than three times of those in NaCMC group. 
Administration of Paliasa leaf extract 125 and 250 
mg/kg was shown to reduce total bilirubin level in 
AT-treated rats. However, the reduction of total 
bilirubin levels in those groups did not reach 
statistical difference compared to AT group. In 
contrast, the administration of higher dose (500 
mg/kg) seemed to improve the total bilirubin level 
significantly. Indeed, the level of total bilirubin in 
rats treated with 500 mg/kg extract ranged 
between 0.131-0.172 mg/dl, which still falls in the 
baseline range (see table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Serum total bilirubin in rats following 28 
days of treatments.  
#p<0.05 compared to NaCMC group.  
*p<0.05 compared to AT group 
 
DISCUSSION 
Bilirubin is a product of heme degradation during 
red blood cell decomposition. The unconjugated 
bilirubin is carried by albumin to the liver to 
undergo conjugation with the enzyme 
glucuronosyl transferase. The conjugation process 
led to formation of water-soluble bilirubin, thus, it 
is easier to be excreted.13 Serum total bilirubin is 
the sum of conjugated and unconjugated bilirubin 
in the serum. From the data, it was found that rats’ 
total bilirubin ranged from 0.090-0.205 mg/dl. 
This range is quite low compared to those in 
humans (0.3 to 1.2 mg/dl.13 It is necessary to 
perform baseline measurement prior to treatment 
to set a standard value of healthy rats. 
 
In this study, rats were administered with toxic 
dose of AT, which is double the therapeutic dose, 
to induce hepatotoxicity in the rats.  Figure 1 
shows that the AT-treated rats experienced a 
significant increase in the serum total bilirubin. 
All animals (100%) in the AT group had elevated 
total bilirubin above normal range, indicating a 
liver dysfunction in those rats. Elevated bilirubin 
total in serum may result from increased 
conjugated and/or unconjugated bilirubin. 
Unfortunately, this study did not measure the 
direct and indirect bilirubin to give a bit of 
information regarding the etiology of 
hyperbilirubinemia in these rats. It has been 
shown that isoniazid can damage hepatocyte due 
to increased stress oxidative, which attacking the 
cell membrane of hepatocytes, leading to 
increased serum ALT and AST.14 Meanwhile, 
mechanism of toxicity in rifampicin-treated rats 
involved a damage in bilirubin transporter, 
leading to cholestasis and increased bilirubin in 
serum.15  
 
Following 28 days of treatments, it is shown that 
Paliasa leaf extract was able to hold further 
increased in total bilirubin. Although there was an 
increase in serum total bilirubin in Paliasa-treated 
rats, it was not significantly different from 
NaCMC group, indicating the elevation was not 
severe. In fact, with higher Paliasa extract dose 
(500 mg/kg) the total bilirubin was still in the 
range of normal baseline, indicating a hepatic 
protection by Paliasa extract in higher dose. It has 
been shown that Paliasa leaf contains antioxidant 
compounds that may beneficial to scavenge free 
radicals.16 The antioxidant compounds of Paliasa 
leaves have been found in its ethanolic extract, i.e 
cycloarthane terpenoid.17 It is suggested that 
Paliasa leaf also have a capacity to improve 
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hepatotoxicity in animals induced by paracetamol, 
which mechanism may involve the increase in 
glutathione production in rat liver.18   
 
CONCLUSION 
Toxic dose of AT in rats induced liver injury that 
was characterized by a significant elevation of 
serum total bilirubin. The administration of 
Paliasa extract at the dose of 500 mg/kg prior to 
AT treatment in rats prevented the elevation of 
serum total bilirubin compared to those without 
Paliasa extract. The use of Paliasa leaf extract may 
find clinical significance to protect liver function 
from AT-induced liver damage. 
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